Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
4
2
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
9 treatments under study, led by Gemcitabine Platinum Based Chemotherapy Cisplatin Or Carboplatin
Research Leaders
6 sponsors active, led by Sandy Srinivas
Related Conditions
Often studied with 15 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
50%
2 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy
177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment.
DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Research Network
Common Treatments
- Gemcitabine Platinum Based Chemotherapy Cisplatin Or Carboplatin1
- Ngs Test For Ddr Alterations1
- Platinum Gemcitabine1
- Avelumab Firstline Maintenance1
- Tbren Dose Level 21
Active Sponsors
- Sandy Srinivas1
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS1
- Ankara University1
- SystImmune Inc.1
- GSK1
Top Investigators
Stanford University
SystImmune Inc.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Related Conditions
- Bladder Cancer2
- Bladder Urothelial Transitional Cell Cancer2
- Bladder Urothelial Transitional Cell Cancer Resectable Precystectomy1
- Metastatic Urothelial Cancer1
- Metastatic Or Locally Advanced Urothelial Cancer1